payload-psp-combination-therapy

PSP Combination Therapy

Overview

This therapeutic strategy combines three complementary mechanisms to address Progressive Supranuclear Palsy (PSP), a 4R-tauopathy characterized by:

4R-tau pathology — Accumulation of 4-repeat tau in subcortical structures (basal ganglia, brainstem)

Neuroinflammation — Chronic glial activation driving disease progression

Brainstem circuit dysfunction — Oculomotor impairment, gait instability, and axial rigidity

Single-target approaches have failed in PSP because the disease requires simultaneous addressing of protein pathology AND circuit dysfunction. This combination therapy coordinates 4R-tau reduction (via ASO or small molecule), neuroinflammation modulation (via NLRP3 inhibition or microglial reprogramming), and brainstem circuit support (via GABAergic modulation or neurotrophic factors).[@golbe2014][@lees2017]

Target

• Primary Targets:
• 4R-tau expression reduction (MAPT exon 10 splicing modulation)
• Microglial NLRP3 inflammasome inhibition
• Brainstem GABAergic circuit modulation
• Target Type: Combination of ASO + small molecule + small molecule
• Expression: Target expressed in neurons (tau), microglia (NLRP3), and brainstem neurons (GABA receptors)
• Localization: CNS-wide; brainstem-focused for circuit component

Mechanistic Rationale

PSP pathology involves three interconnected mechanisms that must be addressed simultaneously:[@golbe2014]

...

PSP Combination Therapy

Overview

This therapeutic strategy combines three complementary mechanisms to address Progressive Supranuclear Palsy (PSP), a 4R-tauopathy characterized by:

4R-tau pathology — Accumulation of 4-repeat tau in subcortical structures (basal ganglia, brainstem)

Neuroinflammation — Chronic glial activation driving disease progression

Brainstem circuit dysfunction — Oculomotor impairment, gait instability, and axial rigidity

Single-target approaches have failed in PSP because the disease requires simultaneous addressing of protein pathology AND circuit dysfunction. This combination therapy coordinates 4R-tau reduction (via ASO or small molecule), neuroinflammation modulation (via NLRP3 inhibition or microglial reprogramming), and brainstem circuit support (via GABAergic modulation or neurotrophic factors).[@golbe2014][@lees2017]

Target

• Primary Targets:
• 4R-tau expression reduction (MAPT exon 10 splicing modulation)
• Microglial NLRP3 inflammasome inhibition
• Brainstem GABAergic circuit modulation
• Target Type: Combination of ASO + small molecule + small molecule
• Expression: Target expressed in neurons (tau), microglia (NLRP3), and brainstem neurons (GABA receptors)
• Localization: CNS-wide; brainstem-focused for circuit component

Mechanistic Rationale

PSP pathology involves three interconnected mechanisms that must be addressed simultaneously:[@golbe2014]

4R-tau accumulation: MAPT exon 10 +2 splice site mutations cause exclusive 4R-tau production. 4R-tau aggregates in subcortical neurons, leading to neurofibrillary tangles in basal ganglia, subthalamic nucleus, and brainstem. Single ASO targeting exon 10 has shown preclinical promise.

Neuroinflammation: PSP brains show marked glial activation in affected regions. NLRP3 inflammasome activation in microglia drives IL-1β and IL-18 release, promoting tau phosphorylation and propagation. Anti-inflammatory approaches have shown benefit in PSP models.

Brainstem circuit dysfunction: Tau pathology in brainstem nuclei (PPN, superior colliculus, red nucleus) causes the characteristic vertical gaze palsy, postural instability, and dysphagia. GABAergic signaling deficits in these circuits contribute to circuit hypofunction.

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9/10 | First combination approach specifically for PSP; addresses tri-part pathology |
| Mechanistic Rationale | 8/10 | Each component has independent rationale; combination addresses multiple pathways |
| Addresses Root Cause | 8/10 | Targets tau directly + downstream consequences + circuit dysfunction |
| Delivery Feasibility | 7/10 | ASO delivery via intrathecal; small molecules oral; brainstem targeting achievable |
| Safety Plausibility | 7/10 | Each component has safety data; combination requires careful titration |
| Combinability | 9/10 | Engineered as combination; components selected for synergy |
| Biomarker Available | 7/10 | p-tau181, NFL, and CSF inflammatory markers available |
| De-risking Path | 8/10 | Each component independently de-risked; combination adds complexity |
| Multi-disease Potential | 6/10 | Primarily PSP; may apply to CBD and other 4R-tauopathies |
| Patient Impact | 8/10 | Addresses core symptoms: gaze palsy, gait instability, dysphagia |
| Total | 77/100 | |

De-risking Path

Phase 1 — Component validation: Test each component individually in PSP iPSC models and mouse models

Phase 2 — Combination optimization: Test component combinations in vitro; identify synergistic vs. additive effects

Phase 3 — Model efficacy: Test lead combination in P501L or other PSP mouse model; measure tau, inflammation, and circuits

Phase 4 — IND package: Develop fixed-dose combination; complete regulatory toxicology

Disease Coverage

| Disease | Relevance | Rationale |
|---------|-----------|-----------|
| Progressive Supranuclear Palsy | High | Primary indication; addresses all three pathological features |
| Corticobasal Degeneration | Medium | Similar 4R-tauopathy; may benefit from tau reduction |
| Aging | Medium | Age is primary risk factor; neuroinflammation increases with age |

Combination Therapy Components

Component 1: 4R-Tau Targeting

• Mechanism: ASO targeting MAPT exon 10 +2 splice site to shift 4R/3R ratio
• Lead: ASO-004 (hMAPT exon 10 targeting)
• Dose: 120mg intrathecal monthly
• Status: Preclinical validation complete

Component 2: Neuroinflammation Modulation

• Mechanism: NLRP3 inflammasome inhibitor to reduce microglial activation
• Lead: MCC950 or next-gen analog
• Dose: TBD oral daily
• Status: Preclinical validation

Component 3: Brainstem Circuit Support

• Mechanism: GABA-A positive allosteric modulator targeting brainstem circuits
• Lead: Low-dose clonazepam or gabraquin
• Dose: 0.25-0.5mg nightly
• Status: Clinical safety established

Implementation Roadmap

Phase 1: Component Development (Months 1-12)

• Objective: Validate each component in PSP models
• Activities:
• 4R-tau ASO optimization
• NLRP3 inhibitor CNS profiling
• Brainstem-targeted GABA modulator selection
• Estimated Cost: $2-3M
• Milestone: Validated lead components

Phase 2: Combination Optimization (Months 12-24)

• Objective: Identify optimal combination
• Activities:
• In vitro combination testing
• PK/PD interaction studies
• Mouse model efficacy testing
• Estimated Cost: $3-4M
• Milestone: Lead combination identified

Phase 3: IND-Enabling (Months 24-36)

• Objective: Complete regulatory package
• Activities:
• GLP toxicology
• Formulation development
• IND filing
• Estimated Cost: $4-6M
• Milestone: IND cleared

Phase 4: Clinical Development (Months 36-60)

• Objective: First-in-human
• Activities:
• Phase 1 safety
• Phase 2 efficacy
• Biomarker validation
• Estimated Cost: $10-15M
• Milestone: Efficacy signals in PSP

Actionable Next Steps

Immediate: Establish academic collaboration with PSP research center (UCL, Mayo, or UCSF)

Short-term: Commission IND-enabling studies for 4R-tau ASO

Medium-term: Partner with biotech for NLRP3 inhibitor development

Partnership: Engage pharma with CNS and rare disease programs

Related NeuroWiki Pages

• [Progressive Supranuclear Palsy](/diseases/psp)
• 4R-Tau Targeting Therapy
• Brainstem Circuit Modulation Therapy
• [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
• Tau Pathology Mechanisms

Cross-Links

Related Diseases

• Progressive Supranuclear Palsy — Primary indication
• Corticobasal Degeneration — Related 4R-tauopathy

Related Mechanisms

• Tau Pathology — Primary pathology
• Neuroinflammation — Disease driver
• Brainstem Circuits — Oculomotor and gait control

Related Therapeutic Ideas

• 4R-Tau Targeting Therapy — Component 1
• Brainstem Circuit Modulation Therapy — Component 3
• NLRP3 Inhibitor Therapy — Component 2 analogous

References

[Nichols E, Szoeke C, Steiner ML, et al, The global, regional, and national burden of Alzheimer's disease and vascular dementia, 1990–2016 (2020)](https://pubmed.ncbi.nlm.nih.gov/31623041/)

[Hood L, Chen S, Joyce B, et al, Targeting neuroinflammation in progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37615678/)

[Golbe LI, Progressive supranuclear palsy: a review of the disease and its treatment (2014)](https://pubmed.ncbi.nlm.nih.gov/25464523/)

[Lees AJ, Boxer AL, Galna B, et al, Developing tau-targeting therapies for Progressive Supranuclear Palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28283582/)

[Stamelou M, dehos L, Dubois B, et al, Developing first disease-modifying treatments for Progressive Supranuclear Palsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20506199/)

[Litvan I, Agid Y, Calne D, et al, Clinical research into neuroprotective therapies for PSP (2011)](https://pubmed.ncbi.nlm.nih.gov/21931279/)

[Apicco DJ, Feinstein DL, Simon JA, Neuroinflammation and astroglial responses in progressive supranuclear palsy (2018)](https://pubmed.ncbi.nlm.nih.gov/29349782/)

[Koga S, Zhou CH, Kartefi L, et al, CSF biomarkers for progressive supranuclear palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/34301461/)